Insulin—Carcinogen or Mitogen? Preclinical and Clinical Evidence from Prostate, Breast, Pancreatic, and Colorectal Cancer Research

References

• . Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008:14
   Google Scholar
• . Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, , eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2008:1205–1241
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–1777
   PubMed Web of Science ®Google Scholar
• . Hemkens LG, Grouven U, Bender R, . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–1744
   PubMed Web of Science ®Google Scholar
• . Colhoun HM; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52(9):1755–1765
   PubMed Web of Science ®Google Scholar
• . Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52(9):1745–1754
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Early communication about safety of Lantus (insulin glargine). July 1, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169722.htm. Accessed September 22, 2009
   Google Scholar
• . American Association of Clinical Endocrinologists. AACE response to insulin glargine cancer risk articles in Diabetologia: June 29, 2009. http://media.aace.com/article_display.cfm?article_id=4932. Accessed September 22, 2009
   Google Scholar
• . American Diabetes Association. Statement from the ADA on studies suggesting a possible link between insulin glargine and cancer. July 2, 2009. http://professional.diabetes.org/News_Display.aspx?TYP=9&CID=71434. Accessed September 20, 2009
   Google Scholar
• . European Association for the Study of Diabetes. Lantus insulin: a possible link with cancer which required further investigation. Dusseldorf, Germany: 2009. http://webcast.easd.org/press/glargine/glargine.htm. Accessed September 22, 2009
   Google Scholar
• . Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009;52(9):1699–1708
   PubMed Web of Science ®Google Scholar
• . Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928
   PubMed Web of Science ®Google Scholar
• . Watson RT, Kanzaki M, Pessin JE. Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocr Rev. 2004;25(2):177–204
   PubMed Web of Science ®Google Scholar
• . Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during homeostasis. Nat Rev Cancer. 2006;6(3):184–192
   PubMed Web of Science ®Google Scholar
• . Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2009;118(5):315–332
   PubMed Web of Science ®Google Scholar
• . Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505–518
   PubMed Web of Science ®Google Scholar
• . Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–854
   PubMed Web of Science ®Google Scholar
• . Slieker LJ, Brooke GS, DiMarchi RD, . Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia. 1997;40( suppl 2):S54–S61
   PubMed Web of Science ®Google Scholar
• . Kurtzhals P, Schäffer L, Sørensen A, . Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005
   PubMed Web of Science ®Google Scholar
• . Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41–49
   PubMed Web of Science ®Google Scholar
• . Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med. 2009;361(15):1475–1485
   PubMed Web of Science ®Google Scholar
• . Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–511
   PubMed Web of Science ®Google Scholar
• . Wang LH, Lin B, Jong SM, . Activation of transforming potential of the human insulin receptor gene. Proc Natl Acad Sci U S A. 1987;84(16):5725–5729
   PubMed Web of Science ®Google Scholar
• . Staiger K, Staiger H, Schweitzer MA, . Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia. 2005;48(9):1898–1905
   PubMed Web of Science ®Google Scholar
• . Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol. 2002;21(3):171–179
   PubMed Web of Science ®Google Scholar
• . Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009;25(1):41–49
   PubMed Web of Science ®Google Scholar
• . Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate. 2002;50(1):1–3
   PubMed Web of Science ®Google Scholar
• . Hsing AW, Chua S Jr, Gao YT, . Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93(10):783–789
   PubMedGoogle Scholar
• . Chokkalingham AP, Pollak M, Fillmore CM, . Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2001;10(5):421–427
   PubMed Web of Science ®Google Scholar
• . Janssen JA, Wildhagen MF, Ito K, . Circulating free insulin-like growth factor (IGF)-1, total IGF-1, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients with a population-based screening with a 4-year inteval. J Clin Endocrinol Metab. 2004;89(9):4391–4396
   PubMed Web of Science ®Google Scholar
• . Staiger K, Hennige AM, Staiger H, Häring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res. 2007;39(1):65–67
   PubMed Web of Science ®Google Scholar
• . Hankinson SE, Willett WC, Golditz GA, . Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998;351(9113):1393–1396
   PubMed Web of Science ®Google Scholar
• . Toniolo P, Bruning PF, Akhmedkhanov A, . Serum insulinlike growth factor-1 and breast cancer. Int J Cancer. 2000;88(5):828–832
   PubMed Web of Science ®Google Scholar
• . Erbel S, Reers C, Eckstein VW, . Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care. 2008;31(6):1105–1111
   PubMed Web of Science ®Google Scholar
• . Fisher WE, Boros LG, Schirmer WJ. Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996;63(1):310–313
   PubMed Web of Science ®Google Scholar
• . Stolzenberg-Solomon RZ, Graubard BI, Chari S, . Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872–2878
   PubMed Web of Science ®Google Scholar
• . Giovannucci E, Pollak MN, Platz EA, . A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000;9(4):345–349
   PubMed Web of Science ®Google Scholar
• . Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044–1050
   PubMed Web of Science ®Google Scholar
• . Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum. 2008;51(5):593–597
   PubMed Web of Science ®Google Scholar
• . Hansen BF. Insulin analogues with increased mitogenic potency—are they safe? Horm Metab Res. 2008;40(6):431–433
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Fonseca V, McGill JB, . Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52(9):1971–1973
   PubMed Web of Science ®Google Scholar
• . Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia. 2009;52(12):2507–2512
   PubMed Web of Science ®Google Scholar
• . Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA. 2010;303(5):446–447
   PubMed Web of Science ®Google Scholar